BioCryst Pharmaceuticals Stock News

Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Ashland Global Holdings, Lyft and Solaredge Technologies, on Thursday. HIG

Q1 2020 BioCryst Pharmaceuticals Inc Earnings Call

Participating with me today are CEO, Jon Stonehouse; CFO, Anthony Doyle; Chief Medical Officer, Dr. Bill Sheridan; Chief Business Officer, Megan Sniecinski; and Chief Commercial Officer, Charlie Gayer

BioCryst (BCRX) delivered earnings and revenue surprises of 7.69% and 78.23%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) fell 2% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share were up 14.29% over the past year to ($0.24),

BioCryst Pharmaceuticals, Inc. (BCRX) today announced financial results for the first quarter ended March 31, 2020, and provided a corporate update. “This is a transformational year for BioCryst as

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week Highs May 5) • Adverum Biotechnologies...

BioCryst Pharmaceuticals, Inc. (BCRX) today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for patent application 16/671,649. The resulting U.S.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted two newly-hired employees inducement options to purchase an a

Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...

Strong gains in April pushed the health care sector near year highs on hopes for new Covid treatments.

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) gapped up prior to trading on Thursday . The stock had previously closed at $3.56, but opened at $3.70. BioCryst Pharmaceuticals shares last trad

During BioCryst's (BCRX) upcoming Q1 earnings call, investor focus will be on the company's progress with the NDA for its HAE drug, Berotralstat, and the study on galidesivir for COVID-19 disease

During BioCryst's (BCRX) upcoming Q1 earnings call, investor focus will be on the company's progress with the NDA for its HAE drug, Berotralstat, and the study on galidesivir for COVID-19 disease

Investors are snapping up shares of BioCryst, which is testing an antiviral drug similar to Gilead's remdesivir on covid-19 patients.